Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Diagnostic Performance of [18F]Fluorocholine and [68Ga]Ga-Psma Pet/Ct in Prostate Cancer: A Comparative Study Publisher



Paymani Z1, 2 ; Rohringer T3 ; Vali R3 ; Loidl W4 ; Alemohammad N5 ; Geinitz H6 ; Langsteger W2, 7 ; Beheshti M2, 8, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, 1411713135, Iran
  2. 2. Department of Nuclear Medicine & Endocrinology, PET-CT Center LINZ, St. Vincent’s Hospital, Ordensklinikum, Linz, 4020, Austria
  3. 3. Department of Diagnostic Imaging, the Hospital for Sick Children, University of Toronto, Toronto, M5G 1X8, ON, Canada
  4. 4. Department of Urology, St. Vincent’s Hospital, Ordensklinikum, Linz, 4020, Austria
  5. 5. Department of Mathematics and Computer Science, Shahed University, Tehran, 3319118651, Iran
  6. 6. Department of Radiation-Oncology, Krankenhaus Barmherzige Schwestern, Ordensklinikum, Linz, 4020, Austria
  7. 7. Department of Nuclear Medicine, Medical University of Vienna, Vienna, 1090, Austria
  8. 8. Department of Nuclear Medicine, University Hospital, RWTH University, Aachen, 52074, Germany
  9. 9. Department of Nuclear Medicine, Paracelsus Medical University, Salzburg, 5020, Austria

Source: Journal of Clinical Medicine Published:2020


Abstract

The current study endeavored to closely compare the detection rate of 68-Gallium labelled prostate-specific membrane antigen ([68Ga]Ga-PSMA) versus [18F]Fluorocholine in men with prostate cancer (PC), to investigate the benefits and pitfalls of each modality in the setting of various patient characteristics. We retrospectively analyzed 29 biopsy-proven PC patients in two categories, staging and restaging, who underwent both scans within a maximum of 30 days of each other. Variables including patient demographics, prostate specific antigen (PSA) level, Gleason score, clinical course, and following treatments were recorded. The number and location of suspicious lesions as well as uptake values were noted. A total of 148 suspicious lesions were detected, of which 70.9% (105/148) were concordantly visualized in both imaging modalities. [68Ga]Ga-PSMA positron emission tomography/computed tomography (PET/CT) revealed a higher number of metastatic lesions per patients (91% vs 78%). The mean of maximum standardized uptake value (SUV max) in concordant lesions was significantly higher in [68Ga]Ga-PSMA compared to [18F]Fluorocholine PET/CT (14.6 ± 8.44 vs. 6.9 ± 3.4, p = 0.001). Discordant lesions were detected by both modalities, but more frequently by [68Ga]Ga-PSMA PET/CT (20.3% in [68Ga]Ga-PSMA versus 8.8% by [18F]Fluorocholine PET/CT). In patients with PSA levels below 1.0 ng/mL and <2.0 ng/mL, [18F]Fluorocholine PET/CT detection rate was half (57% and 55%, respectively) that of [68Ga]Ga-PSMA PET/CT. Tumor, nodes and metastases (TNM) staging, and subsequently patient management, was only influenced in 4/29 patients (14%), particularly by [68Ga]Ga-PSMA PET/CT with PSA values under 0.5 ng/mL. [68Ga]Ga-PSMA PET/CT revealed superior diagnostic performance to [18F]Fluorocholine PET/CT in staging and restaging of PC patients, especially in cases with low PSA levels. However, in a few hormone resistant high-risk PC patients, [18F]Fluorocholine PET/CT may improve overall diagnostic accuracy. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Related Docs
View other Related Docs
1. Multiphasic 68Ga-Psma Pet/Ct in the Detection of Early Recurrence in Prostate Cancer Patients With a Psa Level of Less Than 1 Ng/Ml: A Prospective Study of 135 Patients, Journal of Nuclear Medicine (2020)
2. Pet/Ct and Pet/Mri, Normal Variations, and Artifacts, Clinical Nuclear Medicine: Second Edition (2020)
3. Necessity of Pelvic Lymph Node Irradiation in Patients With Recurrent Prostate Cancer After Radical Prostatectomy in the Psma Pet/Ct Era: A Narrative Review, Biomedicines (2023)
4. An Update on the Role of Mpmri and 68Ga-Psma Pet Imaging in Primary and Recurrent Prostate Cancer, Clinical Genitourinary Cancer (2024)
5. Bone Metastasis in Prostate Cancer: Bone Scan Versus Pet Imaging, Seminars in Nuclear Medicine (2024)
6. Historical Review of Pharmacological Development and Dosimetry of Psma-Based Theranostics for Prostate Cancer, Journal of Radioanalytical and Nuclear Chemistry (2019)
7. Molecular Imaging of Bone Metastases Using Tumor-Targeted Tracers, Quarterly Journal of Nuclear Medicine and Molecular Imaging (2019)
8. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends, Cancers (2021)
Experts (# of related papers)
View all Related Experts
Reyhaneh Manafi-Farid (4)
Nasim Vahidfar (1)
Other Related Docs
9. Optimal Time-Point for 68Ga-Psma-11 Pet/Ct Imaging in Assessment of Prostate Cancer: Feasibility of Sterile Cold-Kit Tracer Preparation?, European Journal of Nuclear Medicine and Molecular Imaging (2018)